DE602006009899D1 - Verwendung von oxycodon zur behandlung von viszeralem schmerz - Google Patents

Verwendung von oxycodon zur behandlung von viszeralem schmerz

Info

Publication number
DE602006009899D1
DE602006009899D1 DE602006009899T DE602006009899T DE602006009899D1 DE 602006009899 D1 DE602006009899 D1 DE 602006009899D1 DE 602006009899 T DE602006009899 T DE 602006009899T DE 602006009899 T DE602006009899 T DE 602006009899T DE 602006009899 D1 DE602006009899 D1 DE 602006009899D1
Authority
DE
Germany
Prior art keywords
oxycodone
treatment
visceral pain
visceral
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006009899T
Other languages
German (de)
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Euro Celtique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006009899(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique SA filed Critical Euro Celtique SA
Publication of DE602006009899D1 publication Critical patent/DE602006009899D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE602006009899T 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz Active DE602006009899D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
DE602006009899D1 true DE602006009899D1 (de) 2009-12-03

Family

ID=35871217

Family Applications (2)

Application Number Title Priority Date Filing Date
DE202006019887U Expired - Lifetime DE202006019887U1 (de) 2005-01-18 2006-01-17 Medikament zur Behandlung von viszeralem Schmerz
DE602006009899T Active DE602006009899D1 (de) 2005-01-18 2006-01-17 Verwendung von oxycodon zur behandlung von viszeralem schmerz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE202006019887U Expired - Lifetime DE202006019887U1 (de) 2005-01-18 2006-01-17 Medikament zur Behandlung von viszeralem Schmerz

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20230170811A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE202006019887U1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
IN2012DN02521A (enExample) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
MA54704A (fr) 2019-01-08 2022-04-13 H Lundbeck As Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
ES2333901T3 (es) 2010-03-02
AP2249A (en) 2011-07-18
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
HK1107933A1 (en) 2008-04-25
NO20074174L (no) 2007-10-17
MY144471A (en) 2011-09-30
KR20190135557A (ko) 2019-12-06
NO338968B1 (no) 2016-11-07
KR20220165797A (ko) 2022-12-15
JP5049139B2 (ja) 2012-10-17
AT9895U1 (de) 2008-05-15
TWI432196B (zh) 2014-04-01
AU2006207498A1 (en) 2006-07-27
DK1838318T3 (da) 2010-01-04
UA85471C2 (ru) 2009-01-26
KR20120089710A (ko) 2012-08-13
ATE446092T1 (de) 2009-11-15
AR052880A1 (es) 2007-04-11
US20150190393A1 (en) 2015-07-09
ME01066B (me) 2012-10-20
PL1838318T3 (pl) 2010-03-31
IL184530A (en) 2015-01-29
EP1838318B1 (en) 2009-10-21
DK200700207U3 (da) 2007-09-28
AU2006207498B2 (en) 2009-11-19
PT1838318E (pt) 2009-12-15
ZA200705231B (en) 2008-06-25
CA2595043A1 (en) 2006-07-27
TW200637554A (en) 2006-11-01
KR20200128451A (ko) 2020-11-12
CN101106996A (zh) 2008-01-16
SI1838318T1 (sl) 2010-02-26
EP1838318A1 (en) 2007-10-03
EA200701541A1 (ru) 2008-02-28
EA013544B1 (ru) 2010-06-30
WO2006077212A1 (en) 2006-07-27
CY1109660T1 (el) 2014-08-13
JP2008526927A (ja) 2008-07-24
RS51069B (sr) 2010-10-31
US9271974B2 (en) 2016-03-01
US20080200493A1 (en) 2008-08-21
KR20210131450A (ko) 2021-11-02
DE202006019887U1 (de) 2007-07-26
KR20070100368A (ko) 2007-10-10
KR20230170811A (ko) 2023-12-19
CA2595043C (en) 2013-11-19
DK200700207U1 (da) 2007-08-24
AP2007004057A0 (en) 2007-08-31
KR20140091782A (ko) 2014-07-22
KR20080106991A (ko) 2008-12-09
IL184530A0 (en) 2007-10-31
NZ555852A (en) 2010-01-29
HRP20090679T1 (hr) 2010-01-31
CN101106996B (zh) 2013-10-23
BRPI0606247A2 (pt) 2009-06-09

Similar Documents

Publication Publication Date Title
ATE399155T1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
EP1755661A4 (en) USE OF GELSOLINE FOR THE TREATMENT OF INFECTIONS
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
ZA200705231B (en) Use of oxycodone for treating visceral pain
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
EP2010184A4 (en) IMPLANTS FOR THE TREATMENT OF DOPAMINE-ASSOCIATED CONDITIONS
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005027251D1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
EP2403501A4 (en) PREENGENOLONE SULFATE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
DE602005015442D1 (de) Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis
DE502005002104D1 (de) Hesperidin zur Behandlung von Epilepsie
DE602004003252D1 (de) Verwendung von 2h-ä1,3ü-oxazinoä3,2-aüindol-derivaten zur behandlung von neuropathischem schmerz

Legal Events

Date Code Title Description
8363 Opposition against the patent